The new “2025 Cataract Pharmaceuticals Market Report” features newly updated data for both the United States and Western Europe, with expanded analysis of surgeon preferences for infection prevention, pupil dilation, and management of inflammation and pain. This year’s report provides deeper insight into the growing adoption of intracameral injections and fixed-combination eye drops, along with a clearer view of how branded, generic, and compounded products are being positioned in clinical practice.
New analysis segments pharmaceutical usage by provider surgical volume, revealing meaningful differences in protocol selection and product mix. The report also includes updated five-year forecasts, expanded coverage of drug and drug-delivery pipelines, and refreshed market share analysis of leading companies to better capture the competitive landscape and where it is heading.
The “2025 Cataract Pharmaceuticals Market Report” provides a comprehensive, data-driven market analysis of the drugs used before, during, and after cataract surgery in the United States and Western Europe. The report examines current utilization patterns and provides five-year forecasts for revenue by product category.
Coverage includes antibiotics, anti-inflammatory agents, mydriatics/cycloplegics, pain management drugs, and intracameral formulations, along with a detailed look at fixed combinations, branded products, generics, and compounded alternatives. The report also explores evolving surgical practices, the growing role of intracameral injections, reimbursement dynamics, and the competitive pipeline shaping the future of cataract pharmaceuticals.
This report provides a focused, data-driven view of the cataract pharmaceuticals market in the United States and Western Europe, examining procedure volumes, drug utilization patterns, competitive dynamics, and the evolving role of intracameral and combination therapies. The report covers drugs used at every stage of the cataract surgery process and connects clinical practice trends with market performance, pricing pressure, and pipeline innovation to deliver a clear picture of where the market stands today—and how it is expected to evolve over the next five years.
2 licensing types are available for this report:
Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.
SINGLE USER LICENSE
ENTERPRISE LICENSE
Pay by credit card or by invoice.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.